Lemon Bottle: What It Is and What It Does

What Lemon Bottle is

“Lemon Bottle” is a trade name rather than a compound. It refers to a cosmetic injection-lipolysis solution that originated in South Korea, built from three ingredients: phosphatidylcholine, the principal phospholipid in lecithin; bromelain, a proteolytic enzyme complex drawn from pineapple stem; and riboflavin, vitamin B2. What distinguishes it from the older lipodissolve formulations is mainly what it leaves out — it carries no sodium deoxycholate. One point belongs at the very top of this page: the branded formulation itself has not been characterised in the peer-reviewed literature. A PubMed search for the trade name returns no results at all. Everything below therefore describes what is known about the three components individually, and says plainly where that evidence is thin, indirect, or drawn from a different formulation altogether.

Where it comes from

Injection lipolysis long predates any of the current brand names. Phosphatidylcholine formulations were used off-label across Europe and South America from the late 1980s onward, initially under the trade name Lipostabil, and the technique picked up the informal labels “lipodissolve” and “mesotherapy”. Almost all of that early work paired phosphatidylcholine with sodium deoxycholate, a bile salt included to hold it in solution — and later analysis suggested the deoxycholate was responsible for much of the cytolytic activity being observed. The Korean cosmetic formulations of the 2020s, of which this is one, position themselves largely on removing deoxycholate and substituting enzyme and vitamin components in its place.

What it does — in plain terms

Phosphatidylcholine is the only one of the three with a substantial injection-lipolysis literature behind it, investigated for decades as an agent that disrupts adipocyte membranes within localised deposits. Bromelain has been shown in cell culture to interfere with adipocyte differentiation and to induce lipolysis in mature fat cells. Riboflavin is the precursor to FAD, the flavin cofactor that mitochondrial acyl-CoA dehydrogenases require in order to carry out fatty-acid beta-oxidation. Whether those three mechanisms combine to any meaningful effect inside a single vial is precisely the question the published record does not answer.

How it works

The phosphatidylcholine component is the mechanistically best-described of the three. Phosphatidylcholine is an amphipathic phospholipid, and the working hypothesis across the injection-lipolysis literature is that when introduced into adipose tissue at sufficient concentration it destabilises adipocyte membranes, causing the cells to rupture and release their stored triglyceride, which is then cleared by ordinary inflammatory and lymphatic routes. That hypothesis carries an important caveat: because classical formulations always included sodium deoxycholate, and deoxycholate is a detergent that lyses cells on its own, the field has never cleanly separated how much of the effect belongs to the phospholipid and how much to the bile salt. A formulation that removes deoxycholate is therefore not simply a gentler version of the old one — it may be operating through a different, and much less characterised, route.

Bromelain is not a single molecule but a mixture of proteolytic enzymes from Ananas comosus. In 3T3-L1 preadipocytes, stem bromelain has been reported to suppress differentiation into mature adipocytes and to induce both apoptosis and lipolysis in cells that had already matured. Bromelain is also widely studied for anti-inflammatory and fibrinolytic activity, which is the usual rationale given for its inclusion in a cosmetic injectable — the suggestion being that it moderates post-procedure swelling. It should be said that the adipocyte findings come from cell culture, where a compound reaches its target at a controlled concentration; that is a considerable distance from an enzyme mixture injected into living tissue, where proteases face inhibitors, dilution and rapid degradation.

Riboflavin's role is the most indirect of the three and the easiest to overstate. Riboflavin is the biosynthetic precursor to flavin adenine dinucleotide, and FAD is the obligatory cofactor for the acyl-CoA dehydrogenases that catalyse the first step of each round of mitochondrial fatty-acid beta-oxidation. Riboflavin is genuinely required for fat oxidation in that specific biochemical sense, and riboflavin deficiency does impair the pathway. What does not follow is that supplying extra riboflavin locally accelerates the pathway in a person who is already replete — a cofactor that is not in short supply is not the step limiting the reaction. Read the riboflavin content as sound biochemistry with an unproven bridge to any local effect.

What the research shows

The honest summary is that the evidence here is uneven and none of it is about this product. Phosphatidylcholine with deoxycholate has been used in large numbers of people and reported in real clinical series, so something is clearly happening in tissue — but those series are largely uncontrolled, they describe a formulation this one deliberately departs from, and the most recent safety reviews are pointedly critical. Bromelain's adipocyte effects rest on cell culture. Riboflavin's connection is cofactor biochemistry rather than any demonstrated local action. And the specific three-part combination has, as far as the indexed literature goes, never been studied at all. The papers below are supplied so a researcher can read the component evidence directly and judge it, not as support for the finished formula.

• Journal of Cutaneous and Aesthetic Surgery, 2018 — A systematic review paired with the authors' own 14-year experience using a phosphatidylcholine and deoxycholate combination in 1,269 patients — by volume the largest body of injection-lipolysis experience in the literature. It is a retrospective clinical series rather than a randomised controlled trial, and it describes the deoxycholate-containing formulation, not this one.
• Plastic and Reconstructive Surgery Global Open, 2016 — An earlier report from the same group on a phosphatidylcholine and deoxycholate cocktail, documenting technique and observed outcomes across a clinical population. Useful mainly as a description of how the method was actually practised; again uncontrolled, and again the deoxycholate formulation.
• Food and Chemical Toxicology, 2013 — In mouse fat tissue, injected phosphatidylcholine with deoxycholic acid altered expression of lipolysis-related genes alongside pro-inflammatory cytokines and hormones. This is the clearest mechanistic evidence that the injection does something measurable in adipose tissue — and it also shows the response is partly inflammatory, not purely a matter of fat clearance.
• Dermatologic Therapy, 2022 — A safety-focused review whose title asks directly whether injection lipolysis with phosphatidylcholine and sodium deoxycholate is worth the risk. It is included here deliberately: it is the counterweight to the clinical series above, and anyone evaluating this class of solution should read the critical case before the favourable one.
• PLoS One, 2012 — In 3T3-L1 adipocytes, stem bromelain inhibited differentiation of preadipocytes into mature fat cells and induced apoptosis and lipolysis in already-mature adipocytes. A cell-culture result, and the basis for bromelain's presence in formulations of this kind.
• European Journal of Pharmacology, 2023 — Riboflavin activated short-chain acyl-CoA dehydrogenase in a cardiac model, with the paper describing FAD's role in the electron transfer that fatty-acid beta-oxidation depends on. Note the model is cardiac hypertrophy and fibrosis, not adipose tissue — it is cited for the cofactor biochemistry, nothing more.

What Lemon Bottle is studied for

Injection lipolysis of localised adipose deposits. The core application across the phosphatidylcholine literature: introducing the solution directly into a discrete fat deposit rather than acting systemically. Reported series concentrate on small, well-defined areas, and the published experience is overwhelmingly with deoxycholate-containing formulations.

Adipocyte differentiation and apoptosis in cell models. 3T3-L1 preadipocytes are the standard in-vitro system for asking whether a compound blocks fat-cell maturation or kills mature adipocytes. Both bromelain and phospholipid work in this space read out as changes in lipid accumulation and viability.

Fatty-acid beta-oxidation cofactor biochemistry. Riboflavin-derived FAD is required by the acyl-CoA dehydrogenase family. Research interest here is in the dependency itself — deficiency states, enzyme activity assays — rather than in any claim that added riboflavin speeds the pathway up.

Comparative safety of injectable lipolytic agents. An active question in the dermatology literature, covering local necrosis, nodule formation, prolonged swelling and scarring across the various formulations. Directly relevant to any comparison between deoxycholate-based and deoxycholate-free solutions.

Storage & handling

Supplied as a ready-made aqueous solution rather than a lyophilized powder, so there is no reconstitution step and no diluent required. Refrigerate at 2–8 °C on receipt and keep the vial in the dark — the riboflavin component is genuinely photosensitive and degrades on light exposure, which is why the vial should stay in its carton between uses. Do not freeze: freeze-thaw cycling can drop the phospholipid out of suspension irreversibly. Discard any vial whose contents turn cloudy, separate into layers, or show visible particulate.